<DOC>
	<DOCNO>NCT01253564</DOCNO>
	<brief_summary>This open-label study ass safety efficacy RO5185426 previously treat metastatic melanoma patient brain metastasis . Patients receive RO5185426 dose 960 mg twice daily orally disease progression unacceptable toxicity occur .</brief_summary>
	<brief_title>A Study RO5185426 Previously Treated Melanoma Patients With Brain Metastases</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Metastatic melanoma ( Stage IV , American Joint Committee Cancer ) BRAF mutation ( cobas 4800 BRAF V600 Mutation Test ) Brain metastasis surgical resection treatment option Patients must fail least one previous treatment brain metastasis Requiring corticosteroid symptom control Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Increasing corticosteroid dose 7 day prior study entry Previous malignancy within past 2 year , except basal squamous cell carcinoma skin carcinoma insitu cervix Concurrent administration anticancer therapy administer study Clinically significant cardiovascular disease event within 6 month prior first dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>